Shares of enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) have been given a consensus rating of “Buy” by the seven brokerages that are currently covering the firm, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have issued a report on the stock in the last year is $33.67.
Several research firms have commented on ENGN. Morgan Stanley restated an “overweight” rating and issued a $40.00 price objective on shares of enGene in a research report on Wednesday, September 11th. Oppenheimer reissued an “outperform” rating and issued a $30.00 price target on shares of enGene in a research report on Tuesday, September 24th.
Check Out Our Latest Stock Analysis on enGene
Insider Activity at enGene
Hedge Funds Weigh In On enGene
Institutional investors have recently made changes to their positions in the business. Logos Global Management LP increased its holdings in enGene by 50.0% in the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after buying an additional 400,000 shares during the last quarter. SR One Capital Management LP bought a new stake in shares of enGene in the 2nd quarter worth approximately $4,715,000. Janus Henderson Group PLC acquired a new position in enGene during the 1st quarter valued at approximately $17,095,000. Finally, Altitude Crest Partners Inc. acquired a new position in shares of enGene during the first quarter valued at $2,039,000. 64.16% of the stock is owned by institutional investors and hedge funds.
enGene Trading Up 9.0 %
NASDAQ ENGN opened at $9.83 on Thursday. The company has a fifty day simple moving average of $6.77 and a two-hundred day simple moving average of $9.63. enGene has a 12-month low of $4.42 and a 12-month high of $43.00. The company has a current ratio of 19.52, a quick ratio of 19.52 and a debt-to-equity ratio of 0.09. The stock has a market cap of $434.15 million, a P/E ratio of -5.72 and a beta of -0.69.
enGene (NASDAQ:ENGN – Get Free Report) last released its earnings results on Tuesday, September 10th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.05. On average, analysts forecast that enGene will post -1.56 earnings per share for the current year.
enGene Company Profile
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Featured Stories
- Five stocks we like better than enGene
- What Are the FAANG Stocks and Are They Good Investments?
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- Best Aerospace Stocks Investing
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.